Literature DB >> 498076

Comparison of four new cell lines from patients with adenocarcinoma of the ovary.

L K Woods, R T Morgan, L A Quinn, G E Moore, T U Semple, K E Stedman.   

Abstract

Permanent human tumor cell lines COLO 110, COLO 316, COLO 319, and COLO 330 were established from four patients with serous cystadenocarcinoma of the ovary. COLO 110 was derived from primary tumor tissue; COLO 316, COLO 319, and COLO 330 were derived from cells in malignant effusions. COLO 110 and COLO 316 grew as monolayers of epithelioid cells in culture; COLO 319 and COLO 330 grew as vermiform, floating colonies of epithelioid cells in culture. Epithelial-like morphology was confirmed by transmission electron microscopy. All four cell lines had marker chromosomes and double minute chromosomes. Giemsa banding revealed chromosomes 1, 3, 6, and 7 were involved in markers in all four lines, and chromosomes 2, 4, 5, 9, 11, and 15 were involved in markers in three of the cell lines. Marker chromosomes with possible homogeneous staining regions were observed in COLO 319. Estrone was elaborated by three of the lines, but neither chorionic gonadotropin, carcinoembryonic antigen, nor estrogen or progesterone receptor proteins were detected. Each cell line demonstrated a distinctive isozyme phenotype. These cell lines are maintained in active culture and in a cell bank for distribution to other investigators.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 498076

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  21 in total

1.  Characterization of four novel epithelial ovarian cancer cell lines.

Authors:  D M Provencher; H Lounis; L Champoux; M Tétrault; E N Manderson; J C Wang; P Eydoux; R Savoie; P N Tonin; A M Mes-Masson
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000-06       Impact factor: 2.416

2.  New human ovarian cell line OVCCR1/sf in serum-free medium.

Authors:  S Jozan; H Roché; F Cheutin; M Carton; B Salles
Journal:  In Vitro Cell Dev Biol       Date:  1992 Nov-Dec

Review 3.  Developing new drugs for ovarian cancer: a challenging task in a changing reality.

Authors:  R M Canetta; S K Carter
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

4.  Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin.

Authors:  R D Christen; D K Hom; D C Porter; P A Andrews; C L MacLeod; L Hafstrom; S B Howell
Journal:  J Clin Invest       Date:  1990-11       Impact factor: 14.808

5.  Establishment and characterization of two new human ovarian cancer cell lines UWOV1 and UWOV2 and a subline UWOV2 (Sf) growing in serum-free conditions: growth characteristics, biochemical, and cytogenetic studies.

Authors:  T Golombick; R Dansey; W R Bezwoda; J Rosendorff
Journal:  In Vitro Cell Dev Biol       Date:  1990-05

6.  A human gallbladder adenocarcinoma cell line.

Authors:  R T Morgan; L K Woods; G E Moore; L McGavran; L A Quinn; T U Semple
Journal:  In Vitro       Date:  1981-06

7.  Experiments with tissue cultures from a human ovarian serous cystadenocarcinoma producing cancer antigen 125 (CA125), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA).

Authors:  I Fukazawa; N Inaba; Y Ota; N Sato; S Shirotake; H Iwasawa; S Sekiya; H Takamizawa; N Suzuki; H Tokita
Journal:  Arch Gynecol Obstet       Date:  1988       Impact factor: 2.344

8.  Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells.

Authors:  P A Andrews; M P Murphy; S B Howell
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

9.  Homozygous deletions on the short arm of chromosome 9 in ovarian adenocarcinoma cell lines and loss of heterozygosity in sporadic tumors.

Authors:  G Chenevix-Trench; J Kerr; M Friedlander; T Hurst; B Sanderson; M Coglan; B Ward; J Leary; S K Khoo
Journal:  Am J Hum Genet       Date:  1994-07       Impact factor: 11.025

Review 10.  Signaling and drug sensitivity.

Authors:  R D Christen; S Isonishi; J A Jones; A P Jekunen; D K Hom; R Kröning; D P Gately; F B Thiebaut; G Los; S B Howell
Journal:  Cancer Metastasis Rev       Date:  1994-06       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.